In cases where only the C797S mutation is present without T790M, NSCLC with drug resistance may still maintain sensitivity to quinazoline-based EGFR inhibitors such as gefitinib, erlotinib, and afatinib (26, 27). The gene discussed is EGFR; the disease is non-small cell lung carcinoma.